Anzeige
Mehr »
Dienstag, 05.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQWL | ISIN: US60458C1045 | Ticker-Symbol: K6S
Tradegate
01.08.25 | 21:58
1,350 Euro
-1,46 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MIRA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MIRA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2901,34021:59

Aktuelle News zur MIRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study211Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain...
► Artikel lesen
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.07.MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain264Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end MIAMI, FLORIDA...
► Artikel lesen
28.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
11.07.MIRA Pharmaceuticals: MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition280SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier...
► Artikel lesen
10.07.Mira Pharmaceuticals: Präklinische Daten für SKNY-1 deuten auf angstlösende Wirkung hin3
10.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
08.07.MIRA Pharmaceuticals sichert sich 2 Millionen US-Dollar durch Block-Verkauf von Aktien14
03.07.MIRA Pharmaceuticals: MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks282With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)...
► Artikel lesen
03.07.MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours10
02.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report5
30.06.Mira Pharmaceuticals berichtet über Ergebnisse von Tierstudien für SKNY-1 Abnehmmittel5
30.06.MIRA Pharmaceuticals: MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition254Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA)...
► Artikel lesen
30.06.EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study2
25.06.MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects261MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for...
► Artikel lesen
24.06.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report1
18.06.MIRA Pharmaceuticals' ketamine analog accepted for publication3
18.06.MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology404MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic...
► Artikel lesen
17.06.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
28.05.MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program252The company will engage in BIO One-on-One Partnering meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, FL...
► Artikel lesen
28.05.MIRA Pharmaceuticals gibt klinische Fortschritte und Akquisitionsupdate bekannt4
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1